Rituximab: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, rituximab is a medication that is "a genetically engineered anti-CD20 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 Entrez protein]) [[antib...) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[medicine]], [[rituximab]] is a [[medication]] that is "a genetically engineered anti-CD20 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 Entrez protein]) [[antibody]] for the treatment of B-cell [[lymphoma]]."<ref>{{MeSH}}</ref> | In [[medicine]], [[rituximab]] is a [[medication]] that is "a genetically engineered anti-CD20 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NP_690605 Entrez protein]) [[antibody]] for the treatment of B-cell [[lymphoma]]."<ref>{{MeSH}}</ref> | ||
Revision as of 21:42, 23 March 2009
In medicine, rituximab is a medication that is "a genetically engineered anti-CD20 (Entrez protein) antibody for the treatment of B-cell lymphoma."[1]
References
- ↑ Anonymous (2024), Rituximab (English). Medical Subject Headings. U.S. National Library of Medicine.
External links
The most up-to-date information about Rituximab and other drugs can be found at the following sites.
- Rituximab - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Rituximab - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Rituximab - Detailed information from DrugBank.